[go: up one dir, main page]

DE60016765D1 - Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind - Google Patents

Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind

Info

Publication number
DE60016765D1
DE60016765D1 DE60016765T DE60016765T DE60016765D1 DE 60016765 D1 DE60016765 D1 DE 60016765D1 DE 60016765 T DE60016765 T DE 60016765T DE 60016765 T DE60016765 T DE 60016765T DE 60016765 D1 DE60016765 D1 DE 60016765D1
Authority
DE
Germany
Prior art keywords
synthetic
papilloma
genes
optimized
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60016765T
Other languages
English (en)
Other versions
DE60016765T2 (de
Inventor
P Neeper
L Mcclements
U Jansen
D Schultz
Ling Chen
Xin-Min Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26847958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60016765(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE60016765D1 publication Critical patent/DE60016765D1/de
Application granted granted Critical
Publication of DE60016765T2 publication Critical patent/DE60016765T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE60016765T 1999-08-25 2000-08-21 Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind Revoked DE60016765T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15072899P 1999-08-25 1999-08-25
US150728P 1999-08-25
US21014300P 2000-06-07 2000-06-07
US210143P 2000-06-07
PCT/US2000/022932 WO2001014416A2 (en) 1999-08-25 2000-08-21 Synthetic papillomavirus genes optimized for expression in human cells

Publications (2)

Publication Number Publication Date
DE60016765D1 true DE60016765D1 (de) 2005-01-20
DE60016765T2 DE60016765T2 (de) 2005-11-24

Family

ID=26847958

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60016765T Revoked DE60016765T2 (de) 1999-08-25 2000-08-21 Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind

Country Status (9)

Country Link
EP (1) EP1212358B1 (de)
JP (1) JP4799789B2 (de)
AT (1) ATE284898T1 (de)
AU (1) AU772611B2 (de)
CA (1) CA2381991A1 (de)
DE (1) DE60016765T2 (de)
ES (1) ES2233437T3 (de)
PT (1) PT1212358E (de)
WO (1) WO2001014416A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
BR0112637A (pt) * 2000-07-21 2003-06-10 Glaxo Group Ltd Sequências do vìrus do papiloma códon-otimizadas
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
ES2284559T3 (es) * 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.
DE50214201D1 (de) * 2001-06-05 2010-03-25 Curevac Gmbh Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20050118139A1 (en) * 2001-08-23 2005-06-02 Lingyi Huang Vaccine using papilloma virus e proteins delivered by viral vector
WO2003047617A2 (en) 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
FR2839072A1 (fr) 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
CN100506999C (zh) * 2003-03-24 2009-07-01 麦克公司 Hpv31l1在酵母中的优化表达
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
BRPI0507579A (pt) * 2004-02-11 2007-07-03 Angeletti P Ist Richerche Bio molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea
RU2373219C2 (ru) * 2004-03-24 2009-11-20 Мерк энд Ко. Инк. Оптимизированная экспрессия hpv 52 l1 в дрожжах
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
EP2059262B1 (de) * 2006-08-28 2013-08-21 Sungkyunkwan University Foundation for Corporate Collaboration Dns-vakzine zur behandlung oder prävention von gebärmutterhalskrebs mit einem hpv-protein codierenden gen
AR065076A1 (es) 2007-01-30 2009-05-13 Transgene Sa Vacuna contra el papilomavirus
BRPI0810305A2 (pt) * 2007-05-15 2018-07-10 Transgene Sa "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição"
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
CN107723299B (zh) * 2011-10-12 2022-02-01 宾夕法尼亚大学理事会 用于人乳头状瘤病毒的疫苗及其使用方法
HK1220905A1 (zh) 2013-03-12 2017-05-19 The Trustees Of The University Of Pennsylvania 用於人乳头状瘤病毒的改进疫苗及其使用方法
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
DE202015009974U1 (de) 2014-12-12 2022-02-17 Curevac Ag Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
TWI890893B (zh) * 2020-11-24 2025-07-21 佳揚生物科技股份有限公司 用於人類乳突病毒的ｄｎａ疫苗及其使用方法
CN113637690A (zh) * 2021-08-18 2021-11-12 武汉华美生物工程有限公司 一种人乳头瘤病毒hpv16型e7活性蛋白的制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679509A (en) * 1993-09-28 1997-10-21 University Of New Mexico Methods and a diagnostic aid for distinguishing a subset of HPV that is associated with an increased risk of developing cervical dysplasia and cervical cancer
US5820868A (en) * 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
WO1996039178A1 (en) * 1995-06-05 1996-12-12 The Wistar Institute Of Anatomy And Biology A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
AU743616B2 (en) * 1997-02-07 2002-01-31 Merck & Co., Inc. Synthetic HIV gag genes
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Also Published As

Publication number Publication date
PT1212358E (pt) 2005-04-29
ES2233437T3 (es) 2005-06-16
JP2003511010A (ja) 2003-03-25
WO2001014416A3 (en) 2001-12-06
AU7063900A (en) 2001-03-19
WO2001014416A2 (en) 2001-03-01
EP1212358B1 (de) 2004-12-15
EP1212358A2 (de) 2002-06-12
DE60016765T2 (de) 2005-11-24
CA2381991A1 (en) 2001-03-01
JP4799789B2 (ja) 2011-10-26
AU772611B2 (en) 2004-05-06
ATE284898T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
DE60016765D1 (de) Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
ATE342916T1 (de) Synthetische hiv gag gene
NO983876L (no) Syntetiske HIV-gener
EP1687329B8 (de) Optimierte expression von hpv-58-l1 in hefe
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
ATE296618T1 (de) Rna krebsimpfstoff und verfahren zu dessen benutzung
NO2018010I1 (no) HPV 31 L1 protein
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
EP1568373A3 (de) Induzierung von zellulärer Immunantwort auf HER2/neu mit Hilfe von Peptid- und Nukleinsäurezubereitungen
MY148656A (en) Optimized expression of hpv 52 l1 in yeast.
HK1053985A1 (zh) 人類多肽引起或導致殺死細胞，包括淋巴腫瘤細胞
HUP0402259A2 (hu) Vakcinák
DE69732029D1 (de) Dna enthaltende impfstoffen
ATE317016T1 (de) Herstellung rekombinanter künstlicher hefe- chromosome, welche das genom des humanen cytomegalovirus enthalten
EP2172214A3 (de) Chlamydia-Antigene und entsprechende DNA-Fragmente sowie Verwendungen davon
ZA200602107B (en) Piroplasmid vaccine
ATE349539T1 (de) In vivo stabilsierung von plasmiden
WO2001073001A3 (en) Establishment of cellular manipulations which enhance oligo-mediated gene targeting
EA199800750A1 (ru) Синтетические гены вич
AU2001292647A1 (en) Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof
AU2002246618A1 (en) Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US

8331 Complete revocation